Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Everolimus; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: None (Observational Study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 40
States / cities: Mobile, Alabama • Chandler, Arizona • Little Rock, Arkansas + 36 more

Conditions: Breast Cancer
Interventions: Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine; Biological · Drug
Lead sponsor: Marker Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 11
States / cities: Tampa, Florida • Westwood, Kansas • Baltimore, Maryland + 7 more

Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 30
States / cities: Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions: [68Ga]Ga-ABY-025; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: trastuzumab, aldesleukin, laboratory biomarker analysis, pharmacological study; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Trastuzumab Deruxtecan, Datopotamab Deruxtecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan, Valemetostat; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions: Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 729
States / cities: Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 560 more

Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Interventions: Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan; Drug · Procedure · Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Fullerton, California • Los Alamitos, California • Los Angeles, California + 6 more

Conditions: HER2-positive Breast Cancer
Interventions: Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 40 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 413
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 286 more

Conditions: Breast Cancer, Brain Metastases
Interventions: ANG1005; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 19
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more

Conditions: Advanced or Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 866 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more

Conditions: Breast Carcinoma
Interventions: eftilagimod alpha, Paclitaxel, placebo; Biological · Drug · Other
Lead sponsor: Immutep S.A.S.; Industry
Eligibility: 18 Years and older
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Whittier, California • Washington D.C., District of Columbia • Rock Hill, South Carolina + 1 more

Conditions: HER2 Expressing Solid Tumors
Interventions: Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202, Dose Level 4, VNX-202; Genetic
Lead sponsor: Vironexis Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 10
States / cities: Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 7 more

Conditions: Breast Neoplasms, Breast Cancer
Interventions: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 8
States / cities: Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more

Conditions: HER2 Negative Breast Cancer
Interventions: Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg, Goserelin 3.6 MG, Adjuvant chemotherapy; Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer With Low to Intermediate HER2 Expression
Interventions: Echocardiogram; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Toremifene Citrate; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 60 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HER2 Positive Breast Cancer
Interventions: tucatinib, capecitabine, trastuzumab, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more

Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
Interventions: XMT-2056; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Stanford, California • Celebration, Florida + 8 more

Conditions: Breast Cancer
Interventions: None (Observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 58
States / cities: Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions: HER2 - primed Dendritic cells, HER3 - primed Dendritic cells; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Search by objective public record fields.

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer